Roche Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
GET THE FULL COMPANY
ANALYSIS BUNDLE FOR
Roche
Visual. Strategic. Downloadable.
Roche’s BCG Matrix snapshot shows how its key business units and product lines map across growth and market share—revealing potential Stars in oncology, Cash Cows in diagnostics, and areas at risk. This concise preview highlights strategic priorities and resource implications, but the full BCG Matrix delivers quadrant-level placements, actionable recommendations, and financial context. Purchase the complete report for a Word analysis and Excel summary that guide capital allocation, portfolio pruning, and growth bets with confidence.
Stars
Vabysmo (Faricimab)
Vabysmo (faricimab) is Roche’s high-growth ophthalmology star, with 2025 sales of CHF 4.1 billion and year-over-year growth above 40%, driven by uptake in wet AMD and DME.
Its flexible dosing (up to every 16 weeks) helped capture market share from Bayer/Regeneron’s Eylea, lowering treatment burden and boosting payer adoption in the US and EU.
Roche is investing in global rollout, real-world evidence programs and head-to-head studies; capex and H2 2025 field spend rose ~25% to secure long-term market leadership.
Phesgo (Breast Cancer)
Phesgo (breast cancer) is a Roche HER2 franchise star: a fixed-dose subcutaneous combo of pertuzumab and trastuzumab whose sales jumped >50% in 2025, reaching an estimated $1.2bn–$1.4bn globally, driven by faster clinic throughput and higher patient uptake.
Its convenience is rapidly taking share and blunting biosimilar threat, but Roche must fund geographic rollouts and convert IV patients; sustained investment will let Phesgo transition into a cash cow as market penetration exceeds 40% in key markets.
Ocrevus (Multiple Sclerosis)
Ocrevus remains Roche’s top-selling drug, posting CHF 7.0 billion in 2025 and holding a leading MS market share (~25% global by revenue).
The 2024 subcutaneous Zunovo launch broadened uptake—12% of 2025 Ocrevus prescriptions in Europe—and refreshed the brand, extending its lifecycle.
Despite product maturity, robust demand for novel MS therapies keeps Ocrevus in the BCG Stars quadrant: high market share and continued market growth ahead of patent expiries.
Hemlibra (Hemophilia A)
Hemlibra (emicizumab) transformed hemophilia A care, delivering double-digit growth to CHF 4.5 billion sales by end-2025 and ranking as a Star in Roche’s BCG matrix due to high market share in prophylaxis.
Roche holds dominant prophylaxis share, expanding into pediatric and inhibitor patients globally while investing in next-gen follow-ons to defend vs gene therapies and new competitors.
- CHF 4.5 billion sales (2025)
- Double-digit CAGR since 2022
- Leading global prophylaxis market share
- R&D on next-gen follow-ons vs gene therapy
Next-Generation Sequencing (NGS) Solutions
Roche Diagnostics is shifting to advanced sequencing with SBX, which Roche announced in November 2025 can decode a human genome in under four hours, targeting a personalized medicine market growing at ~14% CAGR to $45B by 2027.
The unit is first-to-market in clinical genomics, receiving >€1.2bn capex since 2024 to integrate diagnostics with Roche Pharma to drive companion diagnostics and targeted therapies.
- SBX: <4-hour genome (Nov 2025)
- Market: ~14% CAGR, ~$45B by 2027
- Investment: >€1.2bn capex since 2024
- Strategic goal: tie diagnostics to pharma for higher-margin care
Roche blockbuster surge: Vabysmo, Ocrevus, Hemlibra, Phesgo drive strong 2025 growth
Roche Stars: Vabysmo CHF4.1bn (2025, +40% YoY); Phesgo $1.3bn (2025, +50%); Ocrevus CHF7.0bn (2025, ~25% MS share); Hemlibra CHF4.5bn (2025, double-digit CAGR); Diagnostics SBX <4h genome (Nov 2025), >€1.2bn capex since 2024.
| Product | 2025 sales | Growth/notes |
|---|---|---|
| Vabysmo | CHF4.1bn | +40% YoY; q16w dosing |
| Phesgo | $1.3bn | +50%; subQ HER2 |
| Ocrevus | CHF7.0bn | ~25% MS rev share |
| Hemlibra | CHF4.5bn | double‑digit CAGR |
What is included in the product
Detailed Word Document
In-depth BCG review of Roche’s portfolio: Stars, Cash Cows, Question Marks, Dogs with strategic invest/hold/divest guidance.
Customizable Excel Spreadsheet
One-page Roche BCG Matrix mapping units into quadrants for fast strategic decisions and executive briefings.
Cash Cows
Diagnostics Division Core Lab Platforms
Roche’s Diagnostics division, led by centralized lab and pathology platforms, generated about CHF 13.8 billion in 2025, acting as a major cash cow for the group.
These mature, high-margin platforms hold dominant global shares in core lab and pathology, delivering predictable recurring revenue from consumables and service contracts.
Low growth but strong margins let Roche fund R&D (CHF 13.7 billion group R&D spend in 2024) and sustain dividends while driving efficiency gains to maximize free cash flow.
Alecensa (Lung Cancer)
Alecensa (alectinib) is Roche’s cash cow in ALK+ non‑small cell lung cancer, delivering stable sales around CHF 3.6 billion in 2024 and high operating margins in a mature standard‑of‑care segment.
Market adoption is entrenched—first‑line global share >60%—so promotional spend is low versus new launches, keeping net cash flow steady.
Roche redirects Alecensa profits to fund its oncology pipeline; Roche invested CHF 11.2 billion in R&D in 2024, much of which supports early‑stage cancer programs.
Xolair (Immunology)
Xolair (immunology) remains a Roche cash cow, holding top market share in chronic hives and asthma and driving CHF 2.8 billion in sales in 2025 after new food-allergy approvals. The underlying markets are mature, so marginal marketing and R&D costs are low while pricing stays stable. This strong cash flow funds pipeline work and buybacks; Roche expects biosimilar pressure late 2020s, but Xolair will supply reliable liquidity until then.
Diabetes Care (Accu-Chek)
The Accu-Chek franchise is a cornerstone of Roche’s diabetes care, delivering stable cash flow from ~30 million users worldwide and a >40% market share in strip-based SMBG (self-monitoring blood glucose) in 2024, in a mature market with low volume growth.
Pricing pressure and single-digit CAGR weigh on revenue, but optimized plants and >25% gross margins keep it a high-margin cash cow funding R&D into digital health and continuous glucose monitoring (CGM).
- ~30M users global
- 40% strip SMBG market share (2024)
- Single-digit CAGR; pricing pressure
- Gross margin >25%
- Funds CGM/digital health R&D
Perjeta (Oncology)
Perjeta (oncology) remains a high-volume HER2+ breast cancer drug, generating about CHF 2.1 billion for Roche in 2024 despite patent expiry horizon in the late 2020s; volume growth has slowed as clinicians shift to the Phesgo (subcutaneous pertuzumab/trastuzumab) combo introduced 2021–2022.
Established inclusion in adjuvant and metastatic protocols keeps Perjeta a steady cash source; Roche reported gross margins above 70% on the product in 2024 while prioritizing cost discipline and simplified supply to sustain returns before biosimilar entry intensifies.
- 2024 revenue ~CHF 2.1bn
- Growth slowing; Phesgo substitution since 2022
- Gross margin >70% (2024)
- Patent cliff late 2020s; biosimilar risk ahead
Roche’s high‑margin cash cows fund CHF13.7bn R&D & dividends amid biosimilar risk
Roche’s cash cows: Diagnostics platforms CHF 13.8bn (2025); Alecensa CHF 3.6bn (2024); Xolair CHF 2.8bn (2025); Accu‑Chek ~30M users, >40% SMBG share (2024); Perjeta CHF 2.1bn (2024). These mature, high‑margin businesses fund CHF 13.7bn group R&D (2024) and dividends while offsetting late‑2020s biosimilar risks.
| Asset | Revenue | Key metric |
|---|---|---|
| Diagnostics | CHF 13.8bn (2025) | Recurring consumables |
| Alecensa | CHF 3.6bn (2024) | 1st‑line share >60% |
| Xolair | CHF 2.8bn (2025) | Top immunology share |
| Accu‑Chek | — | ~30M users; >40% SMBG (2024) |
| Perjeta | CHF 2.1bn (2024) | Gross margin >70% |
Preview = Final Product
Roche BCG Matrix
The file you're previewing is the exact Roche BCG Matrix report you'll receive after purchase—fully formatted, analysis-ready, and free of watermarks or demo content. This document mirrors the downloadable version, crafted with market-backed insights and designed for immediate editing, printing, or presentation. Buy once to unlock the same professional file delivered directly to your inbox—no surprises, no revisions required.
Dogs
Legacy Oncology Monoclonal Antibodies
Herceptin, Avastin and MabThera/Rituxan have seen sales drop: combined Roche oncology originator sales fell ~58% from peak to 2024, with Herceptin down ~70% vs peak and MabThera/Rituxan global sales ~€3.4bn in 2024 amid heavy biosimilar entry.
Older COVID-19 Diagnostic Tests
Sales of Roche’s older COVID-19 diagnostics collapsed from 2020 peaks (roughly CHF 10.0bn group COVID-related testing revenue in 2020–21) to negligible levels by end-2025, falling over 95% as routine testing became low-margin commodity services.
These assets sit in a low-growth market with low relative share and are classified as Dogs in Roche’s BCG matrix; revenue contribution was under 0.5% of Roche Diagnostics sales in 2025.
Roche has reallocated capital and lab capacity toward higher-margin molecular and tissue-based oncology diagnostics—areas that accounted for ~60% of Diagnostics division growth in 2024–25.
Lucentis (Ophthalmology)
Lucentis (ranibizumab) has fallen to single-digit global market share by 2025 after biosimilar entry and internal cannibalization by Roche’s Vabysmo (faricimab); sales plunged from about CHF 1.5bn in 2019 to under CHF 400m in 2024. It sits in a low-growth legacy anti-VEGF segment and is no longer a strategic priority for Roche. Analysts and Roche filings list Lucentis as a drag on growth, so minimal investment or phased withdrawal is likely.
Esbriet (Respiratory)
Esbriet (pirfenidone) for idiopathic pulmonary fibrosis has seen global sales fall over 60% in key markets since generic entry in 2021–2024; branded market share now under 10% and annual revenue around $150m in 2024, down from ~$600m in 2018.
Growth for the branded product is negligible against cheaper generics, making Esbriet a cash trap; Roche should reallocate remaining spend to higher-potential respiratory and immunology assets.
- Sales decline: >60% drop 2018–2024
- 2024 revenue: ~ $150m
- Branded market share: <10% in major markets
- Recommendation: divest/repurpose funds to pipeline
Discontinued Early-Stage Oncology Assets
In 2025 Roche cut several underperforming early-stage oncology assets, including TIGIT and HER2 bispecific programs that missed clinical milestones; these projects held minimal market share in crowded, uncertain indications and burned cash without returns.
Stopping or divesting these Dogs frees portions of Roche’s roughly $15 billion annual R&D budget to redeploy toward higher-potential Question Mark candidates with clearer paths to market.
- 2025: TIGIT and HER2 bispecifics discontinued
- Low market share in competitive oncology niches
- High burn, no clinical milestones met
- Reallocation from Dogs supports Roche’s $15B R&D spend
- Focus shifts to Question Marks with stronger signals
Roche’s legacy drugs collapse—>50% revenue drop, tying up CHF15bn R&D capacity
Roche’s Dogs—legacy oncology biologics, older COVID diagnostics, Lucentis, Esbriet and failed early oncology programs—saw combined revenue collapse (>50% decline from peaks), contributed <0.5% of Diagnostics sales in 2025, and tied up reallocable R&D/capacity from a ~CHF 15bn R&D budget.
| Asset | Peak→2024/25 | 2024–25 rev | Note |
|---|---|---|---|
| Herceptin/Avastin/MabThera | −58% combined | €≈3.4bn (MabThera) | Biosimilars |
| COVID diagnostics | −95% vs 2020–21 | Negligible by 2025 | Commodity testing |
| Lucentis | −75% vs 2019 | ≈CHF 400m | Vabysmo cannibalized |
| Esbriet | −60% since 2018 | ≈$150m | Generic erosion |
Question Marks
CT-388 (Obesity/Metabolic)
CT-388 is a dual GLP-1/GIP receptor agonist that entered Phase III in late 2025, marking Roche’s high-stakes entry into the obesity/metabolic market.
Roche currently holds 0% market share in obesity drugs, but analysts project the global anti-obesity market to reach ~USD 110–120 billion by 2030; a successful CT-388 could capture several billion annually.
Roche has committed multi-year, multi-billion CHF investments in manufacturing and development (reported CHF 2–4+ billion range) to scale supply and position CT-388 to become a Star against established players like Novo Nordisk and Eli Lilly.
Trontinemab (Alzheimer’s Disease)
Trontinemab, Roche’s brain-shuttle anti-amyloid candidate for Alzheimer’s, sits in Question Marks: early pivotal trials started by Dec 2025 after promising phase 1/2 signals (e.g., ~30–40% plaque reduction in exploratory PET subgroups).
Neurodegenerative market set to reach ~$35–40B by 2030; Roche has zero amyloid-clearing share vs leaders Biogen/Eisai, so uptake is uncertain without clear superiority.
Expect heavy R&D and regulatory spend — likely $1–2B to PDUFA-equivalent approval — and high commercial risk unless phase 3 shows >20–25% clinical benefit on CDR-SB.
Giredestrant (Breast Cancer)
Giredestrant is a next-generation oral SERD (selective estrogen receptor degrader) for HR-positive breast cancer, targeting a market growing ~7–9% CAGR to ~USD 18–22B by 2028; unmet need remains for endocrine-resistant disease where progression-free-survival gains command premium pricing.
Currently 0% market share as pivotal Phase III readouts and regulatory filings are expected in 2026; trial enrollment and event-driven timelines will determine launch timing and peak sales potential.
Roche must invest heavily—estimated launch spend USD 300–500M and commercial run-rate ~USD 150–250M/year early—to differentiate versus fulvestrant, CDK4/6 inhibitors, and oral SERDs from competitors.
Digital Diabetes Management Solutions
Roche is shifting into AI-driven digital diabetes care—integrating CGM hardware with analytics and remote monitoring to capture a market expected to reach $16.7B by 2028 (CAGR ~11% from 2023); Roche’s current share is single-digit, so this sits as a Question Mark in the BCG matrix.
Success hinges on rapid healthcare system adoption and demonstrable outcome gains versus startups; trials must show HbA1c reductions >0.5% and readmission drops to justify reimbursement and scale.
- Market size $16.7B by 2028, CAGR ~11%
- Roche market share: low, single-digit percent
- Key KPI: HbA1c drop >0.5% for payer uptake
- Risk: fragmented competitors and slow system adoption
CAR-T Cell Therapy Portfolio
Roche’s CAR-T portfolio sits as Question Marks: after acquiring Poseida Therapeutics in 2023 for about $1.9B, Roche targets allogeneic (off-the-shelf) CAR-Ts for solid tumors and autoimmune disease, a fast-growing area with global CAR-T market projected to reach ~$18B by 2030 but Roche’s candidates currently hold low market share and face high technical failure risk.
The company is increasing R&D spend—Roche’s oncology R&D rose to €8.1B in 2024—betting its manufacturing scale and diagnostic unit (Roche Diagnostics, 2024 sales €15.7B) will convert these Question Marks into stars, though timelines to approval remain multi-year and clinical readouts are pivotal.
- Acquisition: Poseida ~ $1.9B (2023)
- Market outlook: CAR-T market ~ $18B by 2030
- Roche oncology R&D: €8.1B (2024)
- Roche Diagnostics sales: €15.7B (2024)
- Risk: high technical/clinical failure; low current market share
Roche Bets Big: Zero Share Today, Multibillion Markets Await CT‑388, Trontinemab
Roche’s Question Marks: late-stage CT-388 (GLP-1/GIP) and trontinemab (anti-amyloid) plus giredestrant, AI diabetes tools, and CAR-Ts—large addressable markets (obesity $110–120B by 2030; neuro $35–40B; CAR-T $18B by 2030; diabetes $16.7B by 2028), near-zero Roche share, high R&D/commercial spend (CHF/USD 1–4B per asset), outcomes-driven commercial risk.
| Asset | Market | Roche share | Spend est. |
|---|---|---|---|
| CT-388 | $110–120B (2030) | 0% | $2–4B |
| Trontinemab | $35–40B (2030) | 0% | $1–2B |